TABLE 3.
Comparison of Different Molecular Platforms
| ThyroSeq (n = 66) | ThyGenX/ThyraMIR (n = 52) | ThyroSure (n = 9) | ||||
|---|---|---|---|---|---|---|
| RAS Alone | RAS With Others | RAS Alone | RAS With Others | RAS Alone | RAS With Others | |
| Histology, No. | n = 35 | n = 31 | n = 6 | |||
| Malignant | 4 | 3 | 2 | 10 | 1 | 1 |
| Benign | 19 | 9 | 9 | 10 | 3 | 1 |
| ROM (RAS alone), % | 17 | 18 | 25 | |||
| ROM (RAS with others), % | 25 | 50 | —a | |||
| ROM (overall), % | 20 | 39 | 33 | |||
Abbreviation: ROM, risk of malignancy.
The number was too low for an appropriate calculation.